According to a statement by the company, Pfizer has stopped COVID pill trial after the latest results showed that it did not reduce symptoms, hospitalizations and deaths.
Pfizer has stated it will halt participation in a clinical trial for Paxlovid, its COVID-19 antiviral medication, for standard-risk COVID-19 patients after the most recent findings revealed the medication did not numerically greatly lower symptoms, hospitalizations, or fatalities.
In more than 65 nations, including the United States, Paxlovid, a combination of the antivirals nirmatrelvir and ritonavir, is presently approved or authorized for conditional or emergency use in the treatment of COVID-19 patients at high risk of developing severe illness, including hospitalization or death.
According to a statement made by Pfizer on June 14, it will “cease enrollment into the EPIC-SR trial due to low rate of hospitalization or death in the standard-risk population.”
The business asserted that it will nonetheless incorporate the new information in its impending application to the U.S. Food and Drug Administration (FDA) to request complete authorization for the administration of Paxlovid to high-risk COVID-19 individuals.
“The company will focus efforts on generating further data on PAXLOVID in vulnerable populations, including longer treatment durations in immunocompromised individuals, as well as exploring other clinical development opportunities, such as its potential use in hospitalized patients with severe disease,” Pfizer added.
Patients with COVID-19 who do not have risk factors for serious illness are referred to be standard-risk patients. They may or may not have received vaccinations.
Results From Trial
Paxlovid and a placebo were compared in the August 2021 beginning of the EPIC-SR study in adult patients with symptomatic COVID-19 who are not hospitalized and “are at low risk of progressing to severe illness.”
Pfizer revealed that Paxlovid results fell short of the study’s objective of “self-reported, sustained alleviation of all symptoms for four consecutive days, as compared to placebo” in December 2021.
When contrasted to the placebo group (10 out of 426 hospitalized, with no deaths), the Paxlovid group’s hospitalizations were reduced by 70% (3 out of 428 hospitalizations, with no deaths). But because the findings were not statistically significant, it is possible that chance played a role.
On June 14, Pfizer revealed that an updated assessment of 1,153 patients who had been enrolled through December 2021 had revealed a 51 percent difference between the two groups in terms of hospitalization or death, with five out of 576 patients in the Paxlovid group and 10 out of 569 in the placebo group necessitating hospitalization or passing away. Once more, the outcomes lacked statistical significance.
According to the manufacturer, there was just one death in the placebo group whereas there were none among the patients who took Paxlovid.
People who had received all of their vaccinations and had at least one risk factor for developing severe COVID-19 were initially included in the EPIC-SR investigation; however, after Paxlovid was approved for the cohort in December 2021, this cohort was no longer included in the study. Pfizer then changed its research eligibility requirements to permit participants whose most recent vaccination was 12 months or more ago.
There was a 57 percent risk reduction for hospitalization or death, with three out of 361 in the Paxlovid group and seven out of 360 in the placebo group requiring to be hospitalized or passing away, according to a sub-group analysis of 721 vaccinated individuals with at least one risk factor for progression to severe COVID-19. Pfizer reported that the results were not statistically significant.
Additionally, Paxlovid exhibited a non-significant 62 percent daily reduction in COVID-19-related medical visits across all patients as compared to placebo.
According to a statement from Pfizer’s CEO and chairman, Albert Bourla, the company’s preliminary research findings “support the efficacy and safety profile for PAXLOVID in the treatment of mild-to-moderate COVID-19 patients with at least one risk factor for progressing to severe COVID-19, regardless of vaccination status.”
“With up to 40–50 [percent] of people around the world estimated to be high risk, we believe there remains a significant unmet need for treatment options to help combat this disease, and we will continue to prioritize efforts to advance the development of PAXLOVID,” he added.
Paxlovid decreases COVID-19 hospitalization and mortality by 46%, according to data from a retrospective cohort study conducted in Israel in early June among a highly immunized community. The study said the drug was “more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease.”
The antiviral medication Paxlovid was not successful in avoiding symptomatic COVID-19 infection in household contacts of the COVID-19 patient who took the tablet, according to a second study in which it failed to yield a statistically significant outcome. Pfizer made this announcement in April.
The United States ended up spending more than $10 billion to purchase 20 million courses of Paxlovid from Pfizer, and the White House has been requesting additional funding from Congress to sustain the purchase of additional courses of the antiviral medication, as well as other treatments and booster doses of vaccines.
The Centers for Disease Control and Prevention (CDC) issued a warning in late May that a few individuals taking Paxlovid may encounter a rebound in COVID-19 symptoms, which means they may experience symptoms again after their symptoms have subsided or test positive for COVID-19 after testing negative.
When the rebound occurred, the CDC stated that it might not have been caused by the medication and that it “may be part of the natural history of SARS-CoV-2” in certain individuals, “independent of treatment with Paxlovid and regardless of vaccination status.”
GreatGameIndia is being actively targeted by powerful forces who do not wish us to survive. Your contribution, however small help us keep afloat. We accept voluntary payment for the content available for free on this website via UPI, PayPal and Bitcoin.
Image by Kches16414, CC BY-SA 4.0, via Wikimedia Commons.
Starting the Day With a Scripture-Inspired Roast Helps Center Your Thoughts on Eternal Truths Amid Temporal Pressures
The world can seem chaotic, especially right after we wake up. Many believers start their mornings reaching for something familiar — a hot cup of coffee — yet end up settling for mediocre brews that do little more than deliver a caffeine jolt. The daily grind of life, with its endless distractions, news cycles, and responsibilities, can leave even the most faithful feeling spiritually parched alongside their physical fatigue. What if your morning ritual could do more than wake you up? What if it could ground you in truth, nourish your body with exceptional quality, and quietly advance a kingdom purpose at the same time?
That’s the promise — and the reality — behind Promised Grounds Coffee. This Christian-founded company doesn’t just roast beans; it approaches every step as an act of worship and discipleship. By selecting only the top 10% of specialty-grade beans, ethically sourced from dedicated farmers in Central and South America, and small-batch roasting them with reverence in Austin, Texas, Promised Grounds delivers what many describe as the best coffee available — never burnt, never bland, but rich with origin stories and layered flavors that honor God’s creation.
From the vibrant Psalm 27 Roast (a light, bright medium option) to the bold yet peaceful 2 Timothy 1:7 Decaf, each bag carries a Scripture verse that turns your daily pour into a gentle reminder of faith. And through their Ounce Per Ounce Promise, every ounce of coffee you enjoy provides an equal ounce of clean water to families in need via partnership with Filter of Hope — literally brewing hope for body and soul, one cup at a time.
The challenge for today’s Christians runs deeper than finding a decent cup. In an age of convenience-driven consumerism, it’s easy to support companies that dilute values or remain silent on matters of faith. Many believers want their everyday choices — from what they drink to how they spend — to reflect discipleship rather than just convenience. Promised Grounds solves this by weaving Christian excellence into the entire process: beans nurtured with prayerful stewardship by farming families, roasted as an offering rather than a commodity, and packaged with Bible verses to encourage a mindset of gratitude and purpose from the first sip. Reviewers consistently praise the smooth, rich profiles — whether enjoyed black in a drip maker, iced on a warm day, or shared in fellowship — noting how the quality stands toe-to-toe with premium secular brands while delivering something far more meaningful.
This integration of faith and flavor addresses a real need in Christian households and ministries. Busy parents, church leaders, and remote workers alike report that starting the day with a Scripture-inspired roast helps center their thoughts on eternal truths amid temporal pressures. The coffee’s exceptional character — bright citrus notes in lighter roasts or deep chocolate undertones in bolder ones — comes from meticulous selection and careful roasting that respects the bean’s natural gifts rather than masking them. It’s the kind of coffee that elevates a simple quiet time, fuels productive workdays, or sparks meaningful conversations when shared at Bible studies or outreach events. And because it’s ethically sourced with integrity, every purchase supports sustainable livelihoods for farmers who treat their crops like family harvests.
For those leading churches or small groups, the impact multiplies. Promised Grounds offers bundles and options perfect for hospitality ministries, turning ordinary coffee service into an opportunity to point people toward the living water of Christ. Imagine greeting visitors with a warm cup whose very bag carries God’s Word — a subtle yet powerful witness that aligns with the Great Commission. The company’s Texas roots and commitment to “brewing hope” resonate especially with believers who value American enterprise paired with global compassion.
Of course, quality alone isn’t enough if the experience feels out of reach. Promised Grounds keeps it accessible with practical perks like free shipping on orders over $40, sample sets for discovering favorites, and thoughtful add-ons such as faith-themed mugs. Whether you prefer whole beans for fresh grinding, grounds for convenience, or even bulk options for larger households and ministries, the result is consistently superior coffee that makes discipleship feel integrated rather than added on.
As you consider how to align even the smallest habits with your walk with God, Promised Grounds Coffee stands out as a refreshing solution. It tackles the dual problems of subpar daily sustenance and disconnected consumption by offering a product that genuinely excels in taste while advancing a mission of clean water, farmer dignity, and scriptural encouragement. Believers who make the switch often describe it as more than a beverage upgrade — it becomes part of their rhythm of gratitude, a daily invitation to remember that every good gift comes from above.
If you’re ready to transform your mornings (and perhaps your church gatherings) with coffee that honors both exceptional craftsmanship and Christian values, I encourage you to explore what Promised Grounds has to offer. One sip at a time, you’ll be nourishing your body, refreshing your spirit, and participating in something far greater — all while enjoying what truly is among the best coffee available.
